Proactive Investors - Run By Investors For Investors

Avacta Group appoints Immunocore’s Eliot Forster as non-executive chairman

The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director
handshake
The company, which develops Affimer biotherapeutics and reagents, said Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry

Avacta Group Plc (LON:AVCT) has announced the appointment of Dr Eliot Forster as non-executive chairman to the board with immediate effect.

The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director.

READ: Avacta hails encouraging results to tie-up with Finnish firm, shares gain

The company, which develops Affimer biotherapeutics and reagents, said Forster brings over 25 years of experience in the pharmaceutical and biotechnology industry.

Avacta said most recently he led Immunocore as chief executive officer to become a world-leading immuno-oncology biotech, raising over £230mln in equity and non-dilutive funding as well as securing partnerships with AstraZeneca PLC (LON:AZN) and the Bill & Melinda Gates Foundation.

The early part of Forster's career was at GSK and then he went on to hold a number of senior roles in Pfizer Inc (NYSE:PFE)

Alastair Smith, CEO of Avacta Group, said: “We have an exciting opportunity to build a world-leading and highly valuable biotech based on the Affimer platform.”

He added: ”Eliot's considerable experience, expertise and network will make a material difference to achieving that goal and to delivering maximum value to shareholders.”

View full AVCT profile View Profile

Avacta Group PLC Timeline

CN Research
April 09 2019

Related Articles

researcher at microscope
May 25 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
A doctor's stethoscope and a marijuana plant
February 23 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use